Home > Insider Trading > Filing (0001562180-20-002990)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434418	Constellation Pharmaceuticals Inc	CNST	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1680329	Emma Reeve	C/O Constellation Pharmaceuticals, Inc. 215 First Street, Suite 200 Cambridge MA 02142	Chief Financial Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-04-09	111	$8.76	111	No	4	M	Direct
Common Stock	Disposition	2020-04-09	111	$35.02	0	No	4	S	Direct
Common Stock	Acquisiton	2020-04-09	589	$7.60	589	No	4	M	Direct
Common Stock	Disposition	2020-04-09	589	$35.02	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-04-09	111	$0.00	111	$8.76
Common Stock	Stock Option (right to buy)	Disposition	2020-04-09	589	$0.00	589	$7.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
85,389		2029-03-06	No	4	M	Direct
20,611		2028-03-05	No	4	M	Direct

Footnotes

These trades were made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $35.00 to $35.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023.
This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022.